Annual report pursuant to Section 13 and 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of Preliminary Purchase Consideration (Details)

v3.24.0.1
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of Preliminary Purchase Consideration (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 09, 2023
Apr. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Cash consideration:        
Net cash consideration     $ 2,987 $ 12,847
Common stock     $ 2,994 $ 2,212
Ermont Acquisition        
Cash consideration:        
Cash paid for acquisition $ 3,000      
Less cash acquired (13)      
Net cash consideration 2,987      
Common stock 2,994      
Promissory note 4,569      
Total fair value of consideration transferred 13,000      
Total fair value of consideration $ 10,550      
Kind Therapeutics USA LLC        
Cash consideration:        
Cash paid at closing   $ 10,128    
Release of escrow   2,444    
Severance paid from escrow   556    
Less cash acquired   (2,310)    
Net cash consideration   10,818    
Promissory note   5,634    
Write-off accounts receivable   658    
Write-off of deferred accounts receivable   842    
Total fair value of consideration transferred   $ 17,952